Virological and Immunological Response to HAART Therapy in a Community-Based Cohort of HIV-1-Positive Individuals

Touloumi, Giota; Paparizos, Vasilis; Sambatakou, Helen; Κατσαρού, Όλγα; Chrysos, George; Kordossis, T.; Antoniadou, Anastasia; Hatzitheodorou, Helen; Stavrianeas, Nikos; Gargalianos, Panagiotis; Karafoulidou, Anastasia; Lazanas, Marios; Giamarelou, Helen; Hatzakis, Angelos

doi:10.1310/yn11-xj4l-9yhf-19e4

Cited by 17 publications

(16 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Various studies, which compared NNRTI-and PIbased regimens as the initial treatment regimen, have reported that the virological response of patients under NNRTI-based treatment regimen is higher (9,10,(13)(14). Althogh the main factor for treatment failure has been reported to be resistance development in Europe and the USA, in the present study, treatment noncompliance was noted to be the main reason for treatment failure (10,11).…”

Section: Discussionsupporting

confidence: 51%

The Effect of the Different Treatment Protocols on Virological and Immunological Responses in Patients with HIV/AIDS

Sari¹,

Fincancı²,

Soysal³

2014

Jpn J Infect Dis

View full text Add to dashboard Cite

SUMMARY: This study analyzed the differences between the virological and immunological responses in patients with HIV/AIDS subjected to different treatment protocols. The cases treated with HAART were divided into groups on the basis of treatment protocols. The groups were evaluated with respect to the differences by comparing the virological and immunological responses prior to treatment and at 12 and 24 weeks of therapy. Six different treatment protocols were applied in the treated patients. As the largest clusters, the lopinavir/ritonavir-based patient group (Group 1, n ＝ 29) and efavirenz-based patient group (Group 2, n ＝ 18) were compared. The mean CD 4 and HIV-RNA values of Groups 1 and 2 were 184 and 243 h/ml and 422,266 and 317,684 copies/ml, respectively. At 24 weeks of treatment, the HIV-RNA levels were below detectable values in 86z and 78z of the patients in Groups 1 and 2, respectively ( p À 0.001). The striking outcomes observed in this study demonstrated that the pretreatment HIV-RNA level, CD 4 value, gender, age, and protease inhibitor-or non-nucleoside reverse transcriptase inhibitor-based combined treatment protocols do not cause a significant difference and that patient compliance to treatment is the most important factor associated with treatment success.

show abstract

Section: Discussionsupporting

confidence: 51%

The Effect of the Different Treatment Protocols on Virological and Immunological Responses in Patients with HIV/AIDS

Sari¹,

Fincancı²,

Soysal³

2014

Jpn J Infect Dis

View full text Add to dashboard Cite

show abstract

“…Various randomized clinical trials (24)(25)(26)(27)(28)(29), have shown that 60%-90% of patients treated with HAART achieved sustained suppression of viral load below the detection limit of standard assays.…”

mentioning

confidence: 99%

“…In this study, with initial over all baseline mean CD4 count of 132.9 cells/mm 3 , showed a mean increase in CD4 count of 203.0 cells/mm 3 . Touloumi et al (24) showed that increase in CD4 cell counts is biphasic. It is believed that the initial rapid increase in CD4 cell counts is a result of the redistribution of trapped memory T cells into the peripheral blood from the lymph nodes together with a decrease in activation-induced apoptosis.…”

mentioning

confidence: 99%

Immunological and clinical progress of HIV-infected patients on highly active antiretroviral therapy in north west Ethiopia

Wabe¹,

Alemu²

2012

Gaziantep Med J

View full text Add to dashboard Cite

The survival benefits of highly active antiretroviral therapy (HAART) in HIV infected patients have been studied well in the developed world. In resource poor settings like Ethiopia such treatment was started only in 2003. As a result, the existing treatment guidelines and recommendations are based on data from the developed world. The objective of this study was to determine the immunological and clinical progress in HIV/AIDS patients in one year data review of patients' card who initiated on HAART in Ethiopia. A retrospective cohort study was done based on past medical records of HIV/AIDS patients, using a structured data collection format. All patient cards of one year data with patients who initiated HAART from October 1, 2006 to November 30, 2007 were included in the study. The data collected was analyzed using SPSS for window version 16.0. The majority of the study population (383, 64.2%) were prescribed zidovudine/lamivudine/neverapine (ZDV/3TC/NVP) regimen initially. Overall functional status change showed that ability to work was increased by 31.5%, being ambulatory decreased by 93.4% and bedridden status decreased by 80%. A total of 240 (46.9%) patients have showed functional status improvement. Average mean weight change of 5.9 kg (increment by 11.9%) was seen during a one year follow-up. The patients showed immunological change from 132.883 mean CD4/mm 3 count to 335.87 mean CD4/mm 3 . About 492 (82.4%) patients present with different type of opportunistic infections (OIs) at start of therapy which dramatically dropped to only 40 (6.7%) patient after one year of receiving HAART. HAART initiation has decreased progression of the diseases and improved the patients' quality of life. Most patients have showed a significant increment in their CD4 count. The restoration of CD4 in turn has improved the clinical status of most patients. Despite the significant progression of health of patients, greater immunological and clinical success should be attained by encouraging patients for effective use of those lifesaving drugs with maximal adherence. 2) başlangıçta zidovudin/lamivudin/neverapin (ZDV/3TC/NVP) tedavisi verilmişti. Genelde fonksiyonel durum değişimi, çalışma yeteneğinin %31.5 arttığını, ayakta tedavi edilmenin %93.4 azaldığını, yatağa bağlı kalma durumunun %80 azaldığını gösterdi. Toplam 240 hasta fonksiyonel durum düzelmesi gösterdi. Bir yıllık izleme sırasında 5.9 kg ortalama ağırlık değişimi (%11.9 artma) gözlendi. Hastalar ortalama 132.883 CD4/mm 3 sayımından ortalama 335.87 CD4/mm 3 'e immünolojik değişim gösterdi. Tedavinin başlamasında farklı tipte fırsatçı enfeksiyonu bulunan yaklaşık 492 (%82.4) hasta, HAART tedavisi başlamasından bir yıl sonra dramatik olarak sadece 40'a (%6.7) düştü. HAART tedavisi başlanması hastalığın ilerlemesini azalttı ve hastaların yaşam kalitesini iyileştirdi. Hastaların çoğu CD4 sayılarında anlamlı artışlar gösterdi. CD4'deki düzelme birçok hastanın klinik durumunu iyileştirdi. Hastaların sağlığındaki anlamlı iyileşmeye karşın, hayat kurtaran bu ilaçlara d...

show abstract

“…Bu nedenle çalışmamızda 6., 12., 24. ve 48. ay kontrollerinin sonuçları değerlendirilmiştir. CD4 sayısının yüksek ve immünolojik durumunun daha iyi olduğu dönemde başlana-cak ART'nin hastanın mortalite ve morbiditesini azaltacağı düşünülmekte olup CD4 sayısı <200/ mm 3 iken ART başlanan olgularda AIDS'e ilerleme ve mortalitenin daha yüksek olduğu bildirilmektedir (4,9,10,12) . Etkin bir ART ile viral baskılanmayı takip eden haftalar içinde CD4 sayısının 50 hücre/ mm 3 'e yükselmesi beklenir.…”

Section: Gereç Ve Yöntemunclassified

The Evaluation of Virological and Immunological Response to Antiretroviral Therapy in HIV/AIDS Cases

Çelikbaş¹,

Baykam²,

Ozmen³

et al. 2012

ANKEM Derg

View full text Add to dashboard Cite

show abstract

Virological and Immunological Response to HAART Therapy in a Community-Based Cohort of HIV-1-Positive Individuals

Cited by 17 publications

References 29 publications

The Effect of the Different Treatment Protocols on Virological and Immunological Responses in Patients with HIV/AIDS

The Effect of the Different Treatment Protocols on Virological and Immunological Responses in Patients with HIV/AIDS

Immunological and clinical progress of HIV-infected patients on highly active antiretroviral therapy in north west Ethiopia

The Evaluation of Virological and Immunological Response to Antiretroviral Therapy in HIV/AIDS Cases

Contact Info

Product

Resources

About